•
Dec 31, 2019

BioLife Q4 2019 Earnings Report

Expected Revenue:$9.01M
+64.1% YoY
Expected EPS:-$0.02
140.0% YoY

Key Takeaways

BioLife Solutions reported a strong fourth quarter and full year in 2019, marked by a 52% increase in fourth-quarter revenue to $8.3 million. Strategic acquisitions, including Astero Bio, SAVSU Technologies, and Custom Biogenic Systems, played a significant role in the company's growth.

Fourth quarter revenue increased to $8.3 million, a 52% increase year-over-year.

Full-year revenue reached $27.4 million, up 39% compared to the previous year.

Biopreservation media revenue was $5.2 million for the fourth quarter, a decrease of 5% compared to the fourth quarter of 2018.

2020 revenue is expected to be in the range of $48 million to $53 million, reflecting year-over-year revenue growth of 75% to 94%.

Total Revenue
$8.3M
Previous year: $5.46M
+52.0%
EPS
$0
Previous year: $0.04
-100.0%
Gross margin
62%
Previous year: 69%
-10.1%
Adjusted gross margin
65%
Operating loss
-$1.2M
Gross Profit
$5.15M
Previous year: $3.75M
+37.4%
Cash and Equivalents
$18.5M
Previous year: $30.7M
-39.8%
Free Cash Flow
-$1.32M
Previous year: $425K
-411.4%
Total Assets
$103M
Previous year: $45.5M
+125.5%

BioLife

BioLife

BioLife Revenue by Segment

Forward Guidance

BioLife Solutions anticipates revenue between $48 million and $53 million for 2020, representing a 75% to 94% increase over 2019. The company expects media revenue to grow by 20% to 30% and constitute approximately 55% of total revenue. Freezer sales are projected to account for around 35% of total revenue, with automated thaw and evo product lines each contributing approximately 5%.

Positive Outlook

  • Revenue for 2020 is expected to be in the range of $48 million to $53 million, reflecting year-over-year revenue growth of 75% to 94%.
  • Media revenue is expected to grow between 20% to 30% over 2019.
  • Freezer sales are expected to account for approximately 35% of total revenue.
  • Automated thaw and evo product lines each accounting for approximately 5% of total revenue.
  • We expect to exit 2020 with an adjusted EBITDA (non-GAAP) margin of 20% to 25%.

Challenges Ahead

  • Gross margin for 2020 is expected to be in the range of 58% to 62%.
  • Operating expenses for 2020 are expected to be in the range of $28 to $30 million, which includes $2.8 million of intangible asset amortization expense.
  • Potential Impact of COVID-19 Coronavirus in the Seattle area.
  • We believe we have sufficient inventory to meet previously forecasted biopreservation media demand for the next six to nine months.
  • This is a dynamic situation, with an unknowable magnitude and duration.